Ganymed Gets €65M for Cancer-Specific Antibodies
BioWorld Today Correspondent
Ganymed Pharmaceuticals AG landed one of Europe's landmark private equity deals of 2008, a €65 million (US$82.2 million) fourth financing round that will fund preclinical and early clinical development of a broad pipeline of its cancer-specific antibody therapies in multiple oncology indications.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST